ACELRX PHARMACEUTICALS INC Form SC 13D/A May 24, 2018

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### Schedule 13D

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)

(AMENDMENT NO. 6)\*

AcelRx Pharmaceuticals, Inc.

(Name of Issuer)

**Common Stock** 

(Title of Class of Securities)

00444T100

(CUSIP Number)

Mark Wan

c/o Three Arch Partners

19 South B Street, Suite 14

San Mateo, CA 94401

(650) 529-8000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**COPY TO:** 

# Edgar Filing: ACELRX PHARMACEUTICALS INC - Form SC 13D/A Sean Caplice, Esq.

c/o Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP

1200 Seaport Boulevard, Redwood City, California 94063

(650) 321-2400

May 21, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has pre	eviously filed a statement of	on Schedule 13G	to report the acqu	isition that is the s	subject of this
Schedule 13D, and is filin	g this schedule because of	Rule 13d-1(e), 1	3d-1(f) or 13d-1(g	g), check the follow	wing box

**Note**: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.

CUSIP N	Io. 00444'	T10	13D	Page 2 of 11 Pages
1	NAME (	OF I	REPORTING PERSONS	
2			Partners IV, L.P. (the <u>TAP I</u> V ) E APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
3	(a) SEC US	(b E O		
4	SOURC	E O	F FUNDS	
5	WC CHECK 2(d) OR		X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSU	ANT TO ITEMS
6	CITIZE	NSH	IP OR PLACE OF ORGANIZATION	
NUMB:			SOLE VOTING POWER	
BENEFIO OWNE		8	0 shares. Please see Item 5 for more information. SHARED VOTING POWER	
EAG	СН		0	
REPOR	RTING	9	SOLE DISPOSITIVE POWER	
PERS	SON			
WI		10	0 shares. Please see Item 5 for more information. SHARED DISPOSITIVE POWER	

0 shares.

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  - 0 shares. Please see Item 5 for more information.
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP N	No. 00444T1	00 13D	)	Page 3 of 11 Pages
1	NAME OF	REPORTING PERSONS		
2		Associates IV, L.P. ( <u>TAA I</u> V) HE APPROPRIATE BOX IF A MEMBER	R OF A GROUP (See Instruct	ions)
3	(a) (SEC USE	b) DNLY		
4	SOURCE (	OF FUNDS		
5	WC CHECK B 2(d) OR 2(	OX IF DISCLOSURE OF LEGAL PROCE	EEDINGS IS REQUIRED PU	JRSUANT TO ITEMS
6	CITIZENS	HIP OR PLACE OF ORGANIZATION		
NUMB SHA		SOLE VOTING POWER		
BENEFIO	CIALLY 8 ED BY	0 shares. Please see Item 5 for more info SHARED VOTING POWER	ormation.	
EA	СН			
REPOR		0 shares. SOLE DISPOSITIVE POWER		
Wľ	ТН	0 shares. Please see Item 5 for more info SHARED DISPOSITIVE POWER	ormation.	

0 shares.

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  - 0 shares. Please see Item 5 for more information.
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 00444T100 13D Page 4 of 11 Pages 1 NAME OF REPORTING PERSONS Three Arch Management IV, L.L.C. (<u>TAM IV</u>) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 7 SOLE VOTING POWER **SHARES BENEFICIALLY** 0 shares. Please see Item 5 for more information. 8 SHARED VOTING POWER OWNED BY **EACH** 0 shares. 9 SOLE DISPOSITIVE POWER **REPORTING PERSON** WITH 0 shares. Please see Item 5 for more information. 10 SHARED DISPOSITIVE POWER

0 shares.

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  - 0 shares. Please see Item 5 for more information.
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

OO

CUSIP N	No. 004447	Γ10	13D	Page 5 of 11 Pages
1	NAME (	OF I	REPORTING PERSONS	
2			Partners III, L.P. (the <u>TAP I</u> II ) E APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
3	(a) SEC USI	(b E O		
4	SOURCI	E O	FFUNDS	
5	WC CHECK 2(d) OR		X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSU	JANT TO ITEMS
6	CITIZEN	NSH	IP OR PLACE OF ORGANIZATION	
NUMB SHA			SOLE VOTING POWER	
BENEFI OWNE	CIALLY ED BY	8	0 shares. Please see Item 5 for more information. SHARED VOTING POWER	
EAG REPOF PERS	RTING	9	0 shares. SOLE DISPOSITIVE POWER	
WI		10	0 shares. Please see Item 5 for more information. SHARED DISPOSITIVE POWER	

O shares.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0 shares. Please see Item 5 for more information.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

PN

0%

14

TYPE OF REPORTING PERSON (See Instructions)

CUSIP No. 00444T100		T10	)	13D	Page 6 of 11 Pages
1	NAME (	OF I	REPORTING PERSONS		
2			Associates III, L.P. ( <u>TAA I</u> II ) E APPROPRIATE BOX IF A MEME	BER OF A GROUP (See Ins	tructions)
3	(a) SEC US	(b E O			
4	SOURC	E O	F FUNDS		
5	WC CHECK 2(d) OR		X IF DISCLOSURE OF LEGAL PRO	OCEEDINGS IS REQUIRE	D PURSUANT TO ITEMS
6	CITIZEN	NSH	IP OR PLACE OF ORGANIZATION	1	
NUMBI SHAI		e 7	SOLE VOTING POWER		
BENEFIC OWNE		8	0 shares. Please see Item 5 for more SHARED VOTING POWER	information.	
EAC REPOR	TING	9	0 shares. SOLE DISPOSITIVE POWER		
PERS WIT			0 shares. Please see Item 5 for more	information	
** 11		10	SHARED DISPOSITIVE POWER	OTHINGIOH	

 $0~{\rm shares}.$  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

- 0 shares. Please see Item 5 for more information.
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

11

14 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 00444T100 13D Page 7 of 11 Pages 1 NAME OF REPORTING PERSONS Three Arch Management III, L.L.C. (<u>TAM I</u>II ) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 2 (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF 7 SOLE VOTING POWER **SHARES BENEFICIALLY** 0 shares. Please see Item 5 for more information. 8 SHARED VOTING POWER OWNED BY **EACH** 0 shares. 9 SOLE DISPOSITIVE POWER **REPORTING PERSON** WITH 0 shares. Please see Item 5 for more information. 10 SHARED DISPOSITIVE POWER

0 shares.

- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
  - 0 shares. Please see Item 5 for more information.
- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

OO

Page 8 of 11 Pages CUSIP No. 00444T100 13D 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). Mark Wan (\_Wan ) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) SEC USE ONLY 3 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 6 CITIZENSHIP OR PLACE OF ORGANIZATION **United States** NUMBER OF 7 SOLE VOTING POWER **SHARES BENEFICIALLY** 80,625 shares (all of which are represented by options exercisable within 60 days hereof). 8 SHARED VOTING POWER OWNED BY **EACH** 0 shares. Please see Item 5 for more information. 9 SOLE DISPOSITIVE POWER REPORTING **PERSON** WITH 80,625 shares (all of which are represented by options exercisable within 60 days hereof). 10 SHARED DISPOSITIVE POWER

11	0 shares. Please see Item 5 for more information. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12	0 shares. Please see Item 5 for more information. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14	0% TYPE OF REPORTING PERSON (See Instructions)
	IN

CUSIP No. 00444T100 13D Page 9 of 11 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). Wilfred Jaeger (<u>Jaeger</u>) 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) SEC USE ONLY 3 4 SOURCE OF FUNDS WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) CITIZENSHIP OR PLACE OF ORGANIZATION 6 **United States** NUMBER OF 7 SOLE VOTING POWER **SHARES BENEFICIALLY** 0 shares. 8 SHARED VOTING POWER OWNED BY **EACH** 0 shares. Please see Item 5 for more information. 9 SOLE DISPOSITIVE POWER REPORTING **PERSON** WITH 0 shares. 10 SHARED DISPOSITIVE POWER

11	0 shares. Please see Item 5 for more information. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12	0 shares. Please see Item 5 for more information. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14	0% TYPE OF REPORTING PERSON (See Instructions)
	IN

CUSIP No. 00444T100 13D Page 10 of 11 Pages

#### **Statement on Schedule 13D**

This Amendment No. 6 supplements and amends the Schedule 13D originally filed with the Securities and Exchange Commission on February 25, 2011, as amended May 29, 2012, as amended December 17, 2012, as amended on March 7, 2014, as amended on February 15, 2017 and as amended on October 25, 2017 (as amended, the <u>Schedule 13D</u>). Only those items that are hereby reported are amended; all other items remain unchanged.

#### ITEM 4. PURPOSE OF TRANSACTION.

Item 4 of the Schedule 13D is amended and supplemented by adding the following information to Item 4:

This Schedule 13D relates to (i) Three Arch Partners IV, L.P., a Delaware limited partnership (<u>TAP IV</u>); (ii) Three Arch Associates IV, L.P., a Delaware limited partnership (<u>TAA IV</u>); (iii) Three Arch Partners III, L.P., a Delaware limited partnership (<u>TAP III</u>); (iv) Three Arch Associates III, L.P., a Delaware limited partnership (<u>TAA III</u>); (v) Three Arch Management IV, L.L.C., a Delaware limited liability company (<u>TAM IV</u>); (vi) Three Arch Management III, L.L.C., a Delaware limited liability company (<u>TAM III</u>); (vii) Mark Wan, a United States citizen (<u>Wan</u>); and (vii) Wilfred Jaeger, a United States citizen (<u>Jaeger</u> and together with Wan, the <u>Managing Members</u>). TAP IV, TAA IV, TAP III, TAA III, TAM IV, TAM III and the Managing Members are collectively referred to as the <u>Reporting Persons</u>.

On May 21 2018, the Reporting Persons and certain other affiliates of the Reporting Persons and Leerink Revelation Healthcare Fund I, L.P., Industry Ventures Secondary VIII, L.P. and Kline Hill Partners Fund II LP (the <u>Purchasers</u>) entered into a purchase agreement (the <u>Purchase Agreement</u>) pursuant to which the Reporting Persons agreed to a sale to the Purchasers (the <u>Portfolio Sale</u>) of a portfolio of assets held by the Reporting Persons consisting of the securities of private and public companies, including the 9,367,041 shares of Common Stock (the <u>AcelRx Shares</u>) of AcelRx Pharmaceuticals, Inc. (the <u>Issuer</u>) and other investment interests. The transfer of the AcelRx Shares and the securities of another portfolio asset (such securities together with the AcelRx Shares, the <u>Initial Closing Securities</u>) was consummated at an initial closing on May 21, 2018 to the Purchasers.

The Portfolio Sale was undertaken for portfolio management purposes in connection with the imminent expiration of the terms of the Reporting Persons under their respective governing agreements, as the Reporting Persons were initially formed between 1999 and 2004 with initially contemplated terms of ten years. The Portfolio Sale was undertaken as a result of the imminent dissolution of the Reporting Persons due to the upcoming expiration of the terms under the governing agreements. The Portfolio Sale is not being undertaken as a result of an adverse change in the Reporting Persons views on the prospects of the Issuer, or its businesses, management or directors. Wan, a director of the Issuer and affiliate of the Reporting Persons, will continue serving as a member of the Issuer s Board of Directors after the Portfolio Sale.

The aggregate purchase price to be paid by the Purchasers in the Portfolio Sale is \$30 million in up front consideration, plus a residual amount calculated based on, among other things, the trading price of the AcelRx Shares and certain other securities as of the end of calendar year 2018, up to a maximum aggregate amount of \$12.5 million in additional consideration (the Residual Consideration ). The Initial Closing Securities sold by the Reporting Persons in the Portfolio Sale were priced on an aggregate basis, for total consideration in the range of \$25 million to \$37.5 million, depending upon the amount of Residual Consideration eventually paid.

#### ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

- (a, b) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 6.
- (c) The information requested by this paragraph is incorporated herein by reference to the information provided in Item 4 to this Amendment No. 6.

Except as described above, there were no transactions in the Common Stock effected by the Reporting Persons during the past sixty days.

## ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO

#### SECURITIES OF THE ISSUER.

Item 6 of the Schedule 13D is amended and supplemented by adding the following information to Item 6:

The information requested by this paragraph is incorporated herein by reference to the information provided in Item 4 to this Amendment No. 6.

CUSIP No. 00444T100 13D Page 11 of 11 Pages

#### **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 23, 2018

Three Arch Partners IV, L.P. /s/ Steve Agelopoulos

By Three Arch Management IV, L.L.C. Steve Agelopoulos, by Power of Attorney

Its General Partner

Three Arch Associates IV, L.P. /s/ Steve Agelopoulos

By Three Arch Management IV, L.L.C. Steve Agelopoulos, by Power of Attorney

Its General Partner

Three Arch Partners III, L.P. /s/ Steve Agelopoulos

By Three Arch Management III, L.L.C. Steve Agelopoulos, by Power of Attorney

Its General Partner

Three Arch Associates III, L.P. /s/ Steve Agelopoulos

By Three Arch Management III, L.L.C. Steve Agelopoulos, by Power of Attorney

Its General Partner

Three Arch Management IV, L.L.C. /s/ Steve Agelopoulos

Steve Agelopoulos, by Power of Attorney

Three Arch Management III, L.L.C. /s/ Steve Agelopoulos

Steve Agelopoulos, by Power of Attorney

Mark Wan /s/ Steve Agelopoulos

Steve Agelopoulos, by Power of Attorney

Wilfred Jaeger /s/ Steve Agelopoulos

Steve Agelopoulos, by Power of Attorney